A Phase 3 interventional study of Lebrikizumab and Lebrikizumab-matching Placebo in Dermatitis, Atopic and Eczema, sponsored by Almirall, S.A.. Completed at 48 sites in 8 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-05-20.
Sponsored by Almirall, S.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing lebrikizumab in Dermatitis, Atopic — 4 open to participants now, 7 under way, 4 of them phase 3. lebrikizumab · Dermatitis, Atopic.
Among the 24 studies testing lebrikizumab in Dermatitis, Atopic, this one is the 7th largest by enrollment, is one of 2 that started in 2021, is one of 17 in phase 3, and was the 11th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →4 of the 24 studies testing lebrikizumab in Dermatitis, Atopic are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Australia and 10 more countries
Ages 6 mo–18 yrs
Forefront Dermatology S.C · Sites in United States
Ages 12+
Almirall, S.A.
Ages 12+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 331 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 252 across the 24 interventional studies. Of the 17 that completed or were terminated, 13 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 24 have an industry lead sponsor. The 6 most frequent:
Almirall, S.A. is the lead sponsor of 66 studies on the registry; 9 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.
Almirall, S.A. has 7 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
3 of the studies testing lebrikizumab in Dermatitis, Atopic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06526182Phase 3Almirall, S.A.A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis | 2027-04-25 |
| NCT06906497Johann E Gudjonsson MD PhDLebrikizumab in Moderate-to-severe Atopic Dermatitis | 2027-07 |
| NCT07856134Forefront Dermatology S.CAD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered Outcomes | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies testing lebrikizumab in Dermatitis, Atopic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the efficacy of lebrikizumab compared with placebo in participants not adequately controlled with cyclosporine or for whom cyclosporine is not medically advisable up to Week 16.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lebrikizumab administered subcutaneously (SC), participants will receive 2 injections of lebrikizumab 250 mg at Baseline and Week 2, followed by 1 injection of lebrikizumab 250 milligram (mg) once every two weeks (Q2W) in the induction period up to week 16. Participants who received lebrikizumab 250 mg Q2W during the Induction Period will continue to receive lebrikizumab 250 mg Q2W during the Maintenance Period. In order to maintain the double blind, participants from the lebrikizumab 250 mg Q2W arm will be administered a second injection of blinded placebo during Week 16 and Week 18. From Week 20 up to Week 52, all participants will receive 1 injection of lebrikizumab 250 mg Q2W in Open-label maintenance period.
Biological: Lebrikizumab
Lebrikizumab-matching Placebo administered SC, 250 mg dose, Q2W in the induction period for 16 weeks. Participants will receive 2 injections of lebrikizumab 250 mg at Week 16 and Week 18 followed by 1 injection of lebrikizumab 250 mg Q2W from Week 20 up to Week 52 in Open-label maintenance period.
Drug: Lebrikizumab-matching Placebo
Lebrikizumab solution for injection administered subcutaneously.
Matching Placebo solution for injection administered subcutaneously.
Double-blind Induction Period: Percentage of Participants Who Achieved Eczema Area and Severity Index (EASI) 75 (>=75% Reduction From Baseline in EASI Score) at Week 16
The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. The severity of the clinical signs of AD for each of 4 body regions was scored on a 4-point scale: 0=absent, 1=mild, 2=moderate and 3=severe. The area of AD involvement on each of the 4 anatomic regions was assessed as a percentage by body area: 0=no eruption, 1=1% to 9%, 2=10% to 29%, 3=30% to 49%, 4=50% to 60%, 5=70% to 80% and 6=90% to 100%. The composite index with total score ranged from 0 to 72, where higher scores indicates more severe and or extensive disease.
Time frame: At Week 16
Double-blind Induction Period: Percentage of Participants Who Achieved Investigator Global Assessment (IGA) Score of 0 or 1 and 2-point Improvement at Week 16
The IGA is an instrument used to globally rate the severity of the participants AD. It is based on a 5-point scale ranging from 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate) and 4 (severe), and a score is selected using descriptors that best describe the overall appearance of the lesions at a given time point. The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting (minimal, palpable induration and significant induration). Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear).
Time frame: At Week 16
Double-blind Induction Period: Percentage of Participants Who Achieved a 4-point Improvement in Pruritus Numeric Rating Score (NRS) at Week 16
The Pruritus NRS is an 11-point scale used by participants to rate their worst pruritus (itch) severity over the past 24 hours, with 0 indicating "No itch," and 10 indicating "Worst itch imaginable. Higher score indicates more severity.
Time frame: At Week 16
Double-blind Induction Period: Percentage of Participants Who Achieved EASI 75 (>=75% Reduction From Baseline in EASI Score) at Weeks 2, 4, 8, and 12
The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. The severity of the clinical signs of AD for each of 4 body regions was scored on a 4-point scale: 0=absent, 1=mild, 2=moderate and 3=severe. The area of AD involvement on each of the 4 anatomic regions was assessed as a percentage by body area: 0=no eruption, 1=1% to 9%, 2=10% to 29%, 3=30% to 49%, 4=50% to 60%, 5=70% to 80% and 6=90% to 100%. The composite index with total score ranged from 0 to 72, where higher scores indicates more severe and or extensive disease. Percentage of participants who achieved EASI 75 (\>=75% reduction from baseline in EASI score) at Weeks 2, 4, 8, and 12 were reported
Time frame: At Weeks 2, 4, 8, and12
Double-blind Induction Period: Percentage of Participants Who Achieved EASI 90 (>=90% Reduction From Baseline in EASI Score) at Weeks 2, 4, 8, 12 and 16
The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. The severity of the clinical signs of AD for each of 4 body regions was scored on a 4-point scale: 0=absent, 1=mild, 2=moderate and 3=severe. The area of AD involvement on each of the 4 anatomic regions was assessed as a percentage by body area: 0=no eruption, 1=1% to 9%, 2=10% to 29%, 3=30% to 49%, 4=50% to 60%, 5=70% to 80% and 6=90% to 100%. The composite index with total score ranged from 0 to 72, where higher scores indicates more severe and or extensive disease.
Time frame: At Weeks 2, 4, 8, 12 and 16
Double-blind Induction Period: Percentage of Participants Who Achieved EASI 50 (>=50% Reduction From Baseline in EASI Score) at Weeks 2, 4, 8, 12 and 16
The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. The severity of the clinical signs of AD for each of 4 body regions was scored on a 4-point scale: 0=absent, 1=mild, 2=moderate and 3=severe. The area of AD involvement on each of the 4 anatomic regions was assessed as a percentage by body area: 0=no eruption, 1=1% to 9%, 2=10% to 29%, 3=30% to 49%, 4=50% to 60%, 5=70% to 80% and 6=90% to 100%. The composite index with total score ranged from 0 to 72, where higher scores indicates more severe and or extensive disease.
Time frame: At Weeks 2, 4, 8, 12 and 16
Double-blind Induction Period: Percentage of Participants Who Achieved a 4-point Improvement in Dermatology Life Quality Index (DLQI) at Weeks 2, 4, 8, 12 and 16
The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's quality of life (QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question was scored on a 4-point scale (ranged from 0 to 3) where, 0 = not at all, 1= a little, 2= a lot, 3= very much, giving a total score ranging from 0 (not at all) to 30 (very much). A high score is indicative of a poor QoL.
Time frame: At Weeks 2, 4, 8, 12 and 16
Double-blind Induction Period: Percentage of Participants Who Achieved a 4-point Improvement in Children's Dermatology Life Quality Index (CDLQI) at Weeks 2, 4, 8, 12 and 16
The CDLQI is validated from adolescents younger than age of 16 years, which is based on a set of 10 questions different from those of the DLQI to measure the impact of AD disease on QoL in children during the previous week. Each question is scored as follows: 0=not at all or unanswered, 1 = only a little, 2 = quite a lot and 3 = very much. Question 7 has an added possible response, which was scored as 3. CDLQI equals the sum of the score of each question, ranged from 0 (no impact of skin disease on QoL) to 30 (maximum impact on QoL). Higher scores indicate higher impact on QoL.
Time frame: At Weeks 2, 4, 8, 12 and 16
Double-blind Induction Period: Percentage of Participants Who Achieved a 4- Point Improvement in Skin Pain NRS at Week 16
The Skin Pain NRS is an 11-point scale completed by participants to rate their worst skin pain (example, discomfort or soreness) severity over the past 24 hours, with 0 (indicating "No pain") and 10 (indicating "Worst pain imaginable). Higher scores indicated worse pain.
Time frame: At Week 16
Double-blind Induction Period: Change From Baseline in Body Surface Area (BSA) at Weeks 2, 4, 8, 12 and 16
The BSA assessment estimates the extent of disease or skin involvement with respect to AD and is expressed as a percentage of total body surface. BSA was determined by the Investigator or designee using the participant palm = 1% BSA rule. The participant's palm is measured from the wrist to the proximal interphalangeal and thumb. This higher the BSA %, the more active atopic dermatitis is present. Percent of BSA for a body region = total number of palms in a body region \* % surface area equivalent to 1 palm. Overall percent BSA for an individual is arithmetic mean of % BSA of all 4 body regions and ranges from 0% to 100% with higher values representing greater severity of AD and negative change from baseline indicate no severity.
Time frame: Baseline, Weeks 2, 4, 8, 12 and 16
Double-blind Induction Period: Change From Baseline in Scoring Atopic Dermatitis (SCORAD) at Weeks 8 and 16
SCORAD is a validated clinical tool for assessing the extent and intensity of AD. There are 3 components: A) Surface involvement is assessed as proportion of involved surface area segment by segment by applying the rule of 9s and reported as the sum of all areas, with a score ranging from 0-100. B) Intensity part of the SCORAD consists of 6 items: erythema, oedema, oozing/crusting, excoriation, lichenification, and dryness. Each item graded as: none (0), mild (1), moderate (2), or severe (3). C) Subjective assessment of itch and of sleeplessness is recorded for each symptom using a visual analogue scale (VAS), where 0=no itch (or no sleeplessness) and 10= worst imaginable itch (or sleeplessness), with maximum score of 20. Formula is: A/5+7B/2+C, A: extent (0-100), B: intensity (0-18), C: subjective symptoms (0-20). SCORAD total score ranged from 0 (no disease) to 103 (severe disease). Higher values represent worse outcome and negative change from baseline indicate improvement.
Time frame: Baseline, Weeks 8 and 16
Double-blind Induction Period: Change From Baseline in Pruritus NRS by Week up to Week 16
The Pruritus NRS is an 11-point scale used by participants to rate their worst pruritus (itch) severity over the past 24 hours, with 0 indicating "No itch," and 10 indicating "Worst itch imaginable." Higher scores indicated greater severity and negative change from baseline indicate no severity.
Time frame: Baseline, Weeks 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16
Double-blind Induction Period: Change From Baseline in the Sleep Loss at Week 16 Using Patient-related Outcome (PRO) by Week up to Week 16
Sleep loss was assessed by all participants using a PRO instrument. Participants (and if applicable, with help of parents/caregiver if required) rate their sleep on a 5-point Likert scale (with scores ranging from 0 \[not at all\] to 4 \[unable to sleep at all\]). Higher scores indicated a greater impact and worse outcome; therefore, negative change from baseline indicate less impact.
Time frame: Baseline, Weeks 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16
Double-blind Induction Period: Change From Baseline in Patient-Oriented Eczema Measure (POEM) Total Score at Weeks 4, 8, 12 and 16
The POEM is a 7-item, validated questionnaire completed by the participant (and, if applicable, with help of parents/caregiver if required) to assess disease symptoms. Participants are asked to respond to questions on skin dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping. All answers carry equal weight, with a total possible score ranging from 0 to 28 (answers scored as: No days = 0; 1 to 2 days = 1; 3 to 4 days = 2; 5 to 6 days = 3; every day = 4. Higher scores indicated more severe disease and poor quality of life (QoL); therefore, negative change from baseline indicate improvement in QoL.
Time frame: Baseline, Weeks 4, 8, 12 and 16
Double-blind Induction Period: Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Weeks 2. 4, 8, 12 and 16
The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question was scored on a 4-point scale (ranged from 0 to 3) where, 0 = not at all, 1= a little, 2= a lot, 3= very much, giving a total score ranging from 0 (not at all) to 30 (very much). A high score is indicative of a poor QoL and negative change from baseline indicate improvement in QoL.
Time frame: Baseline, Weeks 2, 4, 8, 12 and 16
Double-blind Induction Period: Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 2. 4, 8, 12 and 16
The CDLQI is validated from adolescents younger than age of 16 years, which is based on a set of 10 questions different from those of the DLQI to measure the impact of AD disease on QoL in children during the previous week. Each question is scored as follows: 0=not at all or unanswered, 1 = only a little, 2 = quite a lot and 3 = very much. Question 7 has an added possible response, which was scored as 3. CDLQI equals the sum of the score of each question, ranged from 0 (no impact of skin disease on QoL) to 30 (maximum impact on QoL). Higher scores indicate higher impact on QoL and negative change from baseline indicate low impact on QoL.
Time frame: Baseline, Weeks 2, 4, 8, 12 and 16
Double-blind Induction Period: Change From Baseline in Skin Pain NRS by Week up to Week 16
The Skin Pain NRS is an 11-point scale completed by participants to rate their worst skin pain (example, discomfort or soreness) severity over the past 24 hours, with 0 (indicating "No pain") to 10 (indicating "Worst pain imaginable). Higher scores indicated worse pain and negative change from baseline indicate no pain.
Time frame: Baseline, Weeks 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16
Double-blind Induction Period: Proportion of Topical Corticosteroids (TCS) Medication Free Days
TCS free days proportion = Number of days participant did not take TCS medication / Number of days from Baseline to Week 16 Date or early discontinuation
Time frame: Baseline up to Week 16
Double-blind Induction Period: Median Time (Days) to TCS-Free Use
Days from first study drug injection to the day participant stopped using all TCS.
Time frame: Baseline up to Week 16
Study was conducted at 54 sites in Austria, Belgium, France, Germany, Italy, Netherlands, Poland, Spain, and United Kingdom. Randomization was stratified by previous use of dupilumab, age (adolescent participants aged \>=12 to \< 18 years comprises 11.8% of the overall population compared to adults aged \>=18 years) and baseline disease severity (IGA 3 vs 4).
| Milestone | Double-blind Induction Period: Lebrikizumab +TCS | Double-blind Induction Period: Placebo +TCS | Open-label Maintenance Period: Lebrikizumab to Lebrikizumab | Open-label Maintenance Period: Placebo to Lebrikizumab |
|---|---|---|---|---|
| Started | 220 | 111 | 0 | 0 |
| Completed | 212 | 100 | 0 | 0 |
| Not completed | 8 | 11 | 0 | 0 |
| Withdrew: Adverse event | 2 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 3 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 5 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 0 | 0 |
| Milestone | Double-blind Induction Period: Lebrikizumab +TCS | Double-blind Induction Period: Placebo +TCS | Open-label Maintenance Period: Lebrikizumab to Lebrikizumab | Open-label Maintenance Period: Placebo to Lebrikizumab |
|---|---|---|---|---|
| Started | 0 | 0 | 212 | 100 |
| Completed | 0 | 0 | 180 | 87 |
| Not completed | 0 | 0 | 32 | 13 |
| Withdrew: Adverse event | 0 | 0 | 7 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 14 | 7 |
| Withdrew: Lack of efficacy | 0 | 0 | 6 | 5 |
| Withdrew: Lost to follow-up | 0 | 0 | 4 | 0 |
| Withdrew: Protocol deviation | 0 | 0 | 1 | 0 |
The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. The severity of the clinical signs of AD for each of 4 body regions was scored on a 4-point scale: 0=absent, 1=mild, 2=moderate and 3=severe. The area of AD involvement on each of the 4 anatomic regions was assessed as a percentage by body area: 0=no eruption, 1=1% to 9%, 2=10% to 29%, 3=30% to 49%, 4=50% to 60%, 5=70% to 80% and 6=90% to 100%. The composite index with total score ranged from 0 to 72, where higher scores indicates more severe and or extensive disease.
| Percentage of participants | Double-blind Induction Period: Lebrikizumab +TCS | Double-blind Induction Period: Placebo +TCS |
|---|---|---|
| Double-blind Induction Period: Percentage of Participants Who Achieved Eczema Area and Severity Index (EASI) 75 (>=75% Reduction From Baseline in EASI Score) at Week 16 | 68.4 | 40.8 |
The IGA is an instrument used to globally rate the severity of the participants AD. It is based on a 5-point scale ranging from 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate) and 4 (severe), and a score is selected using descriptors that best describe the overall appearance of the lesions at a given time point. The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting (minimal, palpable induration and significant induration). Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear).
| Percentage of participants | Double-blind Induction Period: Lebrikizumab +TCS | Double-blind Induction Period: Placebo +TCS |
|---|---|---|
| Double-blind Induction Period: Percentage of Participants Who Achieved Investigator Global Assessment (IGA) Score of 0 or 1 and 2-point Improvement at Week 16 | 42.0 | 24.5 |
The Pruritus NRS is an 11-point scale used by participants to rate their worst pruritus (itch) severity over the past 24 hours, with 0 indicating "No itch," and 10 indicating "Worst itch imaginable. Higher score indicates more severity.
| Percentage of participants | Double-blind Induction Period: Lebrikizumab +TCS | Double-blind Induction Period: Placebo +TCS |
|---|---|---|
| Double-blind Induction Period: Percentage of Participants Who Achieved a 4-point Improvement in Pruritus Numeric Rating Score (NRS) at Week 16 | 49.9 | 29.7 |
The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. The severity of the clinical signs of AD for each of 4 body regions was scored on a 4-point scale: 0=absent, 1=mild, 2=moderate and 3=severe. The area of AD involvement on each of the 4 anatomic regions was assessed as a percentage by body area: 0=no eruption, 1=1% to 9%, 2=10% to 29%, 3=30% to 49%, 4=50% to 60%, 5=70% to 80% and 6=90% to 100%. The composite index with total score ranged from 0 to 72, where higher scores indicates more severe and or extensive disease. Percentage of participants who achieved EASI 75 (\>=75% reduction from baseline in EASI score) at Weeks 2, 4, 8, and 12 were reported
| Percentage of participants | Double-blind Induction Period: Lebrikizumab +TCS | Double-blind Induction Period: Placebo +TCS |
|---|---|---|
| At Week 2 | 9.7 | 6.3 |
| At Week 4 | 28.3 | 19.2 |
| At Week 8 | 54.9 | 31.5 |
| At Week 12 | 64.9 | 41.1 |
The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. The severity of the clinical signs of AD for each of 4 body regions was scored on a 4-point scale: 0=absent, 1=mild, 2=moderate and 3=severe. The area of AD involvement on each of the 4 anatomic regions was assessed as a percentage by body area: 0=no eruption, 1=1% to 9%, 2=10% to 29%, 3=30% to 49%, 4=50% to 60%, 5=70% to 80% and 6=90% to 100%. The composite index with total score ranged from 0 to 72, where higher scores indicates more severe and or extensive disease.
| Percentage of participants | Double-blind Induction Period: Lebrikizumab +TCS | Double-blind Induction Period: Placebo +TCS |
|---|---|---|
| At Week 2 | 1.5 | 0.9 |
| At Week 4 | 15.8 | 6.4 |
| At Week 8 | 28.9 | 10.6 |
| At Week 12 | 42.1 | 21.0 |
| At Week 16 | 42.9 | 20.8 |
The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. The severity of the clinical signs of AD for each of 4 body regions was scored on a 4-point scale: 0=absent, 1=mild, 2=moderate and 3=severe. The area of AD involvement on each of the 4 anatomic regions was assessed as a percentage by body area: 0=no eruption, 1=1% to 9%, 2=10% to 29%, 3=30% to 49%, 4=50% to 60%, 5=70% to 80% and 6=90% to 100%. The composite index with total score ranged from 0 to 72, where higher scores indicates more severe and or extensive disease.
| Percentage of participants | Double-blind Induction Period: Lebrikizumab +TCS | Double-blind Induction Period: Placebo +TCS |
|---|---|---|
| At Week 2 | 30.8 | 23.4 |
| At Week 4 | 58.9 | 46.0 |
| At Week 8 | 75.2 | 59.3 |
| At Week 12 | 80.3 | 68.0 |
| At Week 16 | 82.6 | 65.3 |
The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's quality of life (QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question was scored on a 4-point scale (ranged from 0 to 3) where, 0 = not at all, 1= a little, 2= a lot, 3= very much, giving a total score ranging from 0 (not at all) to 30 (very much). A high score is indicative of a poor QoL.
| Percentage of participants | Double-blind Induction Period: Lebrikizumab +TCS | Double-blind Induction Period: Placebo +TCS |
|---|---|---|
| At Week 2 | 52.8 | 57.1 |
| At Week 4 | 66.1 | 61.9 |
| At Week 8 | 70.5 | 56.1 |
| At Week 12 | 73.1 | 59.6 |
| At Week 16 | 78.0 | 69.6 |
The CDLQI is validated from adolescents younger than age of 16 years, which is based on a set of 10 questions different from those of the DLQI to measure the impact of AD disease on QoL in children during the previous week. Each question is scored as follows: 0=not at all or unanswered, 1 = only a little, 2 = quite a lot and 3 = very much. Question 7 has an added possible response, which was scored as 3. CDLQI equals the sum of the score of each question, ranged from 0 (no impact of skin disease on QoL) to 30 (maximum impact on QoL). Higher scores indicate higher impact on QoL.
| Percentage of participants | Double-blind Induction Period: Lebrikizumab +TCS | Double-blind Induction Period: Placebo +TCS |
|---|---|---|
| At Week 2 | 90.9 | 100 |
| At Week 4 | 68.2 | 62.5 |
| At Week 8 | 90.9 | 100 |
| At Week 12 | 95.5 | 100 |
| At Week 16 | 93.1 | 100 |
The Skin Pain NRS is an 11-point scale completed by participants to rate their worst skin pain (example, discomfort or soreness) severity over the past 24 hours, with 0 (indicating "No pain") and 10 (indicating "Worst pain imaginable). Higher scores indicated worse pain.
| Percentage of participants | Double-blind Induction Period: Lebrikizumab +TCS | Double-blind Induction Period: Placebo +TCS |
|---|---|---|
| Double-blind Induction Period: Percentage of Participants Who Achieved a 4- Point Improvement in Skin Pain NRS at Week 16 | 51.6 | 27.5 |
The BSA assessment estimates the extent of disease or skin involvement with respect to AD and is expressed as a percentage of total body surface. BSA was determined by the Investigator or designee using the participant palm = 1% BSA rule. The participant's palm is measured from the wrist to the proximal interphalangeal and thumb. This higher the BSA %, the more active atopic dermatitis is present. Percent of BSA for a body region = total number of palms in a body region \* % surface area equivalent to 1 palm. Overall percent BSA for an individual is arithmetic mean of % BSA of all 4 body regions and ranges from 0% to 100% with higher values representing greater severity of AD and negative change from baseline indicate no severity.
| Percentage of body surface area | Double-blind Induction Period: Lebrikizumab +TCS | Double-blind Induction Period: Placebo +TCS |
|---|---|---|
| Change at Week 2 | -11.4 ± 15.33 | -10.6 ± 12.04 |
| Change at Week 4 | -19.5 ± 19.22 | -15.3 ± 13.77 |
| Change at Week 8 | -27.3 ± 20.60 | -19.2 ± 17.12 |
| Change at Week 12 | -30.6 ± 21.25 | -22.5 ± 17.06 |
| Change at Week 16 | -32.5 ± 21.44 | -22.1 ± 18.57 |
SCORAD is a validated clinical tool for assessing the extent and intensity of AD. There are 3 components: A) Surface involvement is assessed as proportion of involved surface area segment by segment by applying the rule of 9s and reported as the sum of all areas, with a score ranging from 0-100. B) Intensity part of the SCORAD consists of 6 items: erythema, oedema, oozing/crusting, excoriation, lichenification, and dryness. Each item graded as: none (0), mild (1), moderate (2), or severe (3). C) Subjective assessment of itch and of sleeplessness is recorded for each symptom using a visual analogue scale (VAS), where 0=no itch (or no sleeplessness) and 10= worst imaginable itch (or sleeplessness), with maximum score of 20. Formula is: A/5+7B/2+C, A: extent (0-100), B: intensity (0-18), C: subjective symptoms (0-20). SCORAD total score ranged from 0 (no disease) to 103 (severe disease). Higher values represent worse outcome and negative change from baseline indicate improvement.
| Score on a Scale | Double-blind Induction Period: Lebrikizumab +TCS | Double-blind Induction Period: Placebo +TCS |
|---|---|---|
| Change at Week 8 | -32.1 ± 17.90 | -20.0 ± 18.04 |
| Change at Week 16 | -36.8 ± 20.40 | -23.7 ± 21.25 |
The Pruritus NRS is an 11-point scale used by participants to rate their worst pruritus (itch) severity over the past 24 hours, with 0 indicating "No itch," and 10 indicating "Worst itch imaginable." Higher scores indicated greater severity and negative change from baseline indicate no severity.
| Score on a Scale | Double-blind Induction Period: Lebrikizumab +TCS | Double-blind Induction Period: Placebo +TCS |
|---|---|---|
| Change at Week 2 | -1.543 ± 1.6304 | -1.113 ± 1.7468 |
| Change at Week 3 | -2.199 ± 2.0960 | -1.420 ± 2.1401 |
| Change at Week 4 | -2.351 ± 2.2558 | -1.450 ± 2.3924 |
| Change at Week 5 | -2.771 ± 2.4152 | -1.485 ± 2.4553 |
| Change at Week 6 | -3.053 ± 2.3975 | -1.711 ± 2.5330 |
| Change at Week 7 | -3.204 ± 2.4643 | -1.823 ± 2.5263 |
| Change at Week 8 | -3.080 ± 2.4552 | -1.856 ± 2.5670 |
| Change at Week 9 | -3.283 ± 2.5105 | -1.861 ± 2.5872 |
| Change at Week 10 | -3.245 ± 2.6101 | -1.529 ± 2.7489 |
| Change at Week 11 | -3.285 ± 2.5484 | -1.776 ± 2.7302 |
| Change at Week 12 | -3.388 ± 2.6195 | -1.853 ± 2.3583 |
| Change at Week 13 | -3.326 ± 2.6697 | -2.053 ± 2.5284 |
| Change at Week 14 | -3.313 ± 2.6843 | -1.948 ± 2.4181 |
| Change at Week 15 | -3.366 ± 2.5291 | -1.938 ± 2.5245 |
| Change at Week 16 | -3.476 ± 2.5453 | -2.183 ± 2.4246 |
Sleep loss was assessed by all participants using a PRO instrument. Participants (and if applicable, with help of parents/caregiver if required) rate their sleep on a 5-point Likert scale (with scores ranging from 0 \[not at all\] to 4 \[unable to sleep at all\]). Higher scores indicated a greater impact and worse outcome; therefore, negative change from baseline indicate less impact.
| Score on a Scale | Double-blind Induction Period: Lebrikizumab +TCS | Double-blind Induction Period: Placebo +TCS |
|---|---|---|
| Change at Week 2 | -0.603 ± 0.6985 | -0.493 ± 0.8407 |
| Change at Week 3 | -0.816 ± 0.8809 | -0.673 ± 1.0262 |
| Change at Week 4 | -0.875 ± 0.9387 | -0.577 ± 1.0885 |
| Change at Week 5 | -0.942 ± 0.9646 | -0.607 ± 1.1342 |
| Change at Week 6 | -0.998 ± 0.9088 | -0.613 ± 1.0641 |
| Change at Week 7 | -1.038 ± 0.9388 | -0.661 ± 1.1119 |
| Change at Week 8 | -0.974 ± 0.9941 | -0.708 ± 1.1500 |
| Change at Week 9 | -1.052 ± 0.9352 | -0.668 ± 1.0604 |
| Change at Week 10 | -1.091 ± 0.9624 | -0.560 ± 1.1349 |
| Change at Week 11 | -1.040 ± 0.9966 | -0.676 ± 1.0938 |
| Change at Week 12 | -1.123 ± 1.0281 | -0.721 ± 1.0768 |
| Change at Week 13 | -1.069 ± 0.9776 | -0.797 ± 1.1037 |
| Change at Week 14 | -1.072 ± 1.0446 | -0.809 ± 1.0751 |
| Change at Week 15 | -1.096 ± 0.9819 | -0.756 ± 1.0891 |
| Change at Week 16 | -1.201 ± 0.9775 | -0.857 ± 1.0615 |
The POEM is a 7-item, validated questionnaire completed by the participant (and, if applicable, with help of parents/caregiver if required) to assess disease symptoms. Participants are asked to respond to questions on skin dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping. All answers carry equal weight, with a total possible score ranging from 0 to 28 (answers scored as: No days = 0; 1 to 2 days = 1; 3 to 4 days = 2; 5 to 6 days = 3; every day = 4. Higher scores indicated more severe disease and poor quality of life (QoL); therefore, negative change from baseline indicate improvement in QoL.
| Score on a Scale | Double-blind Induction Period: Lebrikizumab +TCS | Double-blind Induction Period: Placebo +TCS |
|---|---|---|
| Change at Week 4 | -8.4 ± 6.82 | -4.7 ± 6.42 |
| Change at Week 8 | -10.9 ± 7.45 | -5.2 ± 6.65 |
| Change at Week 12 | -11.3 ± 8.08 | -5.1 ± 7.25 |
| Change at Week 16 | -11.9 ± 8.01 | -5.8 ± 7.18 |
The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question was scored on a 4-point scale (ranged from 0 to 3) where, 0 = not at all, 1= a little, 2= a lot, 3= very much, giving a total score ranging from 0 (not at all) to 30 (very much). A high score is indicative of a poor QoL and negative change from baseline indicate improvement in QoL.
| Score on a Scale | Double-blind Induction Period: Lebrikizumab +TCS | Double-blind Induction Period: Placebo +TCS |
|---|---|---|
| Change at Week 2 | -4.6 ± 5.54 | -4.5 ± 6.00 |
| Change at Week 4 | -7.1 ± 6.54 | -5.4 ± 6.86 |
| Change at Week 8 | -8.3 ± 7.03 | -5.7 ± 7.89 |
| Change at Week 12 | -8.7 ± 7.38 | -5.9 ± 7.90 |
| Change at Week 16 | -9.5 ± 7.40 | -8.1 ± 7.62 |
The CDLQI is validated from adolescents younger than age of 16 years, which is based on a set of 10 questions different from those of the DLQI to measure the impact of AD disease on QoL in children during the previous week. Each question is scored as follows: 0=not at all or unanswered, 1 = only a little, 2 = quite a lot and 3 = very much. Question 7 has an added possible response, which was scored as 3. CDLQI equals the sum of the score of each question, ranged from 0 (no impact of skin disease on QoL) to 30 (maximum impact on QoL). Higher scores indicate higher impact on QoL and negative change from baseline indicate low impact on QoL.
| Score on a Scale | Double-blind Induction Period: Lebrikizumab +TCS | Double-blind Induction Period: Placebo +TCS |
|---|---|---|
| Change at Week 2 | -2.9 ± 3.41 | -3.6 ± 3.25 |
| Change at Week 4 | -5.1 ± 4.76 | -4.3 ± 4.65 |
| Change at Week 8 | -6.6 ± 6.69 | -6.9 ± 4.82 |
| Change at Week 12 | -7.7 ± 7.60 | -7.4 ± 6.30 |
| Change at Week 16 | -7.7 ± 6.91 | -6.8 ± 5.73 |
The Skin Pain NRS is an 11-point scale completed by participants to rate their worst skin pain (example, discomfort or soreness) severity over the past 24 hours, with 0 (indicating "No pain") to 10 (indicating "Worst pain imaginable). Higher scores indicated worse pain and negative change from baseline indicate no pain.
| Score on a Scale | Double-blind Induction Period: Lebrikizumab +TCS | Double-blind Induction Period: Placebo +TCS |
|---|---|---|
| Change at Week 2 | -1.546 ± 1.7978 | -0.905 ± 1.9170 |
| Change at Week 3 | -2.152 ± 2.1719 | -1.316 ± 2.2680 |
| Change at Week 4 | -2.308 ± 2.2457 | -1.271 ± 2.4880 |
| Change at Week 5 | -2.589 ± 2.3577 | -1.333 ± 2.4462 |
| Change at Week 6 | -2.862 ± 2.4428 | -1.309 ± 2.5079 |
| Change at Week 7 | -2.886 ± 2.4473 | -1.656 ± 2.4816 |
| Change at Week 8 | -2.872 ± 2.4975 | -1.711 ± 2.7208 |
| Change at Week 9 | -3.017 ± 2.4897 | -1.598 ± 2.5693 |
| Change at Week 10 | -3.017 ± 2.6017 | -1.382 ± 2.7463 |
| Change at Week 11 | -3.116 ± 2.6230 | -1.572 ± 2.6465 |
| Change at Week 12 | -3.115 ± 2.6181 | -1.520 ± 2.5976 |
| Change at Week 13 | -3.140 ± 2.5568 | -1.788 ± 2.4726 |
| Change at Week 14 | -3.035 ± 2.6733 | -1.683 ± 2.4462 |
| Change at Week 15 | -3.138 ± 2.6062 | -1.781 ± 2.6443 |
| Change at Week 16 | -3.302 ± 2.5844 | -1.831 ± 2.5766 |
TCS free days proportion = Number of days participant did not take TCS medication / Number of days from Baseline to Week 16 Date or early discontinuation
| Proportion of Days | Double-blind Induction Period: Lebrikizumab +TCS | Double-blind Induction Period: Placebo +TCS |
|---|---|---|
| Double-blind Induction Period: Proportion of Topical Corticosteroids (TCS) Medication Free Days | 0.224 ± 0.3491 | 0.151 ± 0.3032 |
Days from first study drug injection to the day participant stopped using all TCS.
| Days | Double-blind Induction Period: Lebrikizumab +TCS | Double-blind Induction Period: Placebo +TCS |
|---|---|---|
| Double-blind Induction Period: Median Time (Days) to TCS-Free Use | NA (NA to NA) | NA (NA to NA) |
Collected over Double-blind Induction Period: Day 1 to Week 16; Open-label Maintenance Period: Week 16 to Week 52. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-blind Induction Period: Lebrikizumab +TCS | 0/220 (0%) | 3/220 (1.4%) | 84/220 (38.2%) |
| Double-blind Induction Period: Placebo +TCS | 0/111 (0%) | 1/111 (0.9%) | 31/111 (27.9%) |
| Open-label Maintenance Period: Lebrikizumab to Lebrikizumab | 0/212 (0%) | 12/212 (5.7%) | 108/212 (50.9%) |
| Open-label Maintenance Period: Placebo to Lebrikizumab | 0/100 (0%) | 4/100 (4%) | 48/100 (48%) |
| Event | Double-blind Induction Period: Lebrikizumab +TCS | Double-blind Induction Period: Placebo +TCS | Open-label Maintenance Period: Lebrikizumab to Lebrikizumab | Open-label Maintenance Period: Placebo to Lebrikizumab |
|---|---|---|---|---|
| Cutaneous T-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/220 | 0/111 | 0/212 | 1/100 |
| Autoimmune thyroiditisEndocrine disorders | 0/220 | 0/111 | 0/212 | 1/100 |
| Abdominal painGastrointestinal disorders | 0/220 | 0/111 | 0/212 | 1/100 |
| Uterine polypReproductive system and breast disorders | 0/220 | 0/111 | 0/212 | 1/100 |
| Diabetes mellitusMetabolism and nutrition disorders | 0/220 | 0/111 | 2/212 | 0/100 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/220 | 0/111 | 2/212 | 0/100 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 0/220 | 1/111 | 1/212 | 0/100 |
| BronchitisInfections and infestations | 0/220 | 0/111 | 1/212 | 0/100 |
| Lower respiratory tract infectionInfections and infestations | 0/220 | 0/111 | 1/212 | 0/100 |
| Respiratory tract infectionInfections and infestations | 0/220 | 0/111 | 1/212 | 0/100 |
| Event | Double-blind Induction Period: Lebrikizumab +TCS | Double-blind Induction Period: Placebo +TCS | Open-label Maintenance Period: Lebrikizumab to Lebrikizumab | Open-label Maintenance Period: Placebo to Lebrikizumab |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 28/220 | 14/111 | 52/212 | 16/100 |
| ConjunctivitisInfections and infestations | 25/220 | 2/111 | 25/212 | 11/100 |
| Conjunctivitis allergicEye disorders | 18/220 | 3/111 | 18/212 | 11/100 |
| Upper respiratory tract infectionInfections and infestations | 8/220 | 7/111 | 17/212 | 6/100 |
| COVID-19Infections and infestations | 8/220 | 7/111 | 13/212 | 4/100 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 0/220 | 0/111 | 12/212 | 2/100 |
| HeadacheNervous system disorders | 6/220 | 6/111 | 0/212 | 0/100 |
| Oral herpesInfections and infestations | 11/220 | 3/111 | 0/212 | 0/100 |
Full Analysis Set (FAS) included all randomized participants and were analyzed under the treatment group as randomized.
| Age, Continuous(Years) | Double-blind Induction Period: Lebrikizumab +TCS | Double-blind Induction Period: Placebo +TCS | Total |
|---|---|---|---|
| Mean | 33.7 ± 14.85 | 34.1 ± 15.24 | 33.8 ± 14.96 |
| Sex: Female, Male(Participants) | Double-blind Induction Period: Lebrikizumab +TCS | Double-blind Induction Period: Placebo +TCS | Total |
|---|---|---|---|
| Female | 100 | 56 | 156 |
| Male | 120 | 55 | 175 |
| Ethnicity (NIH/OMB)(Participants) | Double-blind Induction Period: Lebrikizumab +TCS | Double-blind Induction Period: Placebo +TCS | Total |
|---|---|---|---|
| Hispanic or Latino | 14 | 14 | 28 |
| Not Hispanic or Latino | 197 | 93 | 290 |
| Unknown or Not Reported | 9 | 4 | 13 |
| Race (NIH/OMB)(Participants) | Double-blind Induction Period: Lebrikizumab +TCS | Double-blind Induction Period: Placebo +TCS | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 1 | 3 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 0 | 5 |
| White | 206 | 104 | 310 |
| More than one race | 0 | 2 | 2 |
| Unknown or Not Reported | 7 | 2 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2021 to primary completion in Jan 2023, 13 months.
Results were first posted in Nov 2024, 1 year 9 months after primary completion. A results delay was requested in Jan 2024.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 13 months is below that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lebrikizumab